Avian Mycoplasmosis in Poultry: Chronic Respiratory Disease and Diagnostic Approaches

Introduction

Avian mycoplasmosis represents a group of economically significant infectious diseases of poultry caused by pathogenic mycoplasmas, primarily Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS). These cell wall deficient bacteria belong to the class Mollicutes and are characterized by their small genome size, fastidious growth requirements, and ability to cause chronic respiratory disease in chickens and turkeys. MG is the primary etiological agent of chronic respiratory disease (CRD), while MS is associated with infectious synovitis and respiratory tract infections. Both pathogens are transmitted vertically through the egg and horizontally via respiratory aerosols, fomites, and direct contact. The global distribution of these pathogens, combined with their ability to evade host immune responses and persist in flocks, necessitates robust diagnostic and control programs. This article provides an exhaustive review of the biology, clinical presentation, diagnostic methodologies, and control measures for avian mycoplasmosis, with emphasis on molecular and serological approaches.

Etiology and Pathogenesis

Mycoplasmas are the smallest self-replicating prokaryotes, lacking a peptidoglycan cell wall, which renders them intrinsically resistant to beta-lactam antibiotics. MG and MS possess a trilaminar cell membrane rich in cholesterol, which they acquire from the host environment. Their genomes are approximately 1.0 Mb in size, encoding a limited set of metabolic pathways, making them dependent on host-derived nutrients. Pathogenicity is mediated by adhesion organelles (e.g., GapA and CrmA in MG) that facilitate attachment to respiratory epithelial cilia, leading to ciliostasis, epithelial cell damage, and inflammation. MS additionally expresses variable surface lipoproteins (VlhA) that undergo phase variation, contributing to immune evasion.

The pathogenesis of CRD involves a complex interplay between the mycoplasma and secondary pathogens. MG infection alone can cause mild to moderate respiratory signs, but co-infection with respiratory viruses (e.g., infectious bronchitis virus, Newcastle disease virus) or bacteria (e.g., Escherichia coli, Ornithobacterium rhinotracheale) exacerbates disease severity. A cross-sectional study in commercial free-range layers demonstrated complex pathogen interactions in upper respiratory tract infections, highlighting that polymicrobial infections are common and that MG and MS frequently co-occur with other respiratory agents [1]. Similarly, co-infection with Cryptosporidium baileyi and MS was shown to enhance MS colonization and aggravate tissue damage in chickens, indicating that parasitic co-infections can modulate mycoplasmal pathogenesis [2].

Clinical Signs and Pathology

Chickens

In chickens, MG infection typically manifests as chronic respiratory disease characterized by rales, coughing, sneezing, nasal discharge, and conjunctivitis. In laying hens, egg production may decline by 10-20%, and eggshell quality deteriorates. Airsacculitis is a common postmortem finding, with thickened, opaque air sacs containing caseous exudate. MS infection in chickens can present as respiratory disease similar to MG or as infectious synovitis, with lameness, swollen joints, and breast blisters. The synovial form is more common in broilers and is associated with poor growth and increased condemnation at slaughter.

Turkeys

Turkeys are highly susceptible to MG, which causes sinusitis, tracheitis, and severe airsacculitis. Clinical signs include infraorbital sinus swelling, dyspnea, and decreased feed intake. Mortality can be significant, especially in young poults. MS in turkeys primarily causes respiratory disease and synovitis, with lameness and sternal bursitis being prominent features. A regional pathogen surveillance study of free-ranging wild turkeys in North Carolina detected MG and MS antibodies, indicating that wild turkeys can serve as reservoirs for these pathogens [3].

Pathological Findings

Gross lesions in CRD include catarrhal tracheitis, fibrinous airsacculitis, and pericarditis. Histologically, there is mucosal hyperplasia, loss of cilia, and infiltration of lymphocytes, plasma cells, and macrophages. In chronic cases, lymphoid follicle formation is observed in the mucosa. MS synovitis is characterized by synovial membrane hyperplasia, heterophilic infiltration, and fibrin deposition in joint spaces.

Diagnostic Approaches

Accurate diagnosis of avian mycoplasmosis requires a combination of serological, molecular, and culture-based methods. The choice of diagnostic test depends on the purpose (e.g., flock screening, confirmation of clinical disease, vaccine strain differentiation) and the stage of infection.

Serological Diagnostics

Serological assays detect antibodies against MG and MS and are widely used for flock monitoring and certification. The most common serological tests are the rapid serum agglutination (RSA) test, hemagglutination inhibition (HI) test, and enzyme-linked immunosorbent assay (ELISA). RSA is a simple, inexpensive screening test that uses stained antigen; however, it has lower specificity and can yield false positives due to cross-reactivity with other mycoplasmas or nonspecific agglutinins. HI is more specific and is often used as a confirmatory test, but it is labor-intensive and requires fresh red blood cells. Commercial ELISA kits (using generic terms) offer high throughput and objective quantification of antibody levels, and they are available for both MG and MS. Serological evidence of MG and MS exposure has been documented in trafficked parrots and macaws in Colombia, suggesting that psittacine birds may act as carriers and introduce mycoplasmas into poultry populations [4].

Molecular Diagnostics

Molecular methods, particularly polymerase chain reaction (PCR), have become the gold standard for direct detection of mycoplasmal DNA. Conventional PCR targeting the 16S rRNA gene or species-specific genes (e.g., mgc2 for MG, vlhA for MS) provides high sensitivity and specificity. Real-time PCR (qPCR) allows quantification of pathogen load and is amenable to high-throughput testing. A multiplex TaqMan real-time PCR assay has been developed for differential identification of wild-type and vaccine strains of MG, enabling discrimination between field infection and vaccine response [5]. This is critical for vaccination programs where live vaccines are used.

Isothermal amplification methods, such as loop-mediated isothermal amplification (LAMP), offer field-deployable alternatives to PCR. A high-throughput colorimetric LAMP assay for MG detection, combined with intelligent algorithm-assisted analysis, has been described, providing rapid visual readout suitable for resource-limited settings [6]. Another field-ready colorimetric LAMP assay using rapid DNA extraction has been validated for MG detection in poultry samples, demonstrating comparable sensitivity to qPCR [7].

Culture and Isolation

Mycoplasma culture remains the definitive diagnostic method but is slow and technically demanding. MG and MS require specialized media (e.g., Frey's medium supplemented with swine serum, yeast extract, and nicotinamide adenine dinucleotide for MS). Colonies on agar have a characteristic "fried egg" appearance. Culture is essential for antimicrobial susceptibility testing and epidemiological typing. Molecular typing methods, such as multilocus sequence typing (MLST) and vlhA gene sequencing, provide high-resolution discrimination of strains. A 14-year study in Italy using molecular typing of MS in industrial and backyard poultry revealed considerable genetic diversity and identified persistent clones circulating in different production systems [8].

Diagnostic Algorithm

The following Mermaid diagram illustrates a recommended diagnostic workflow for avian mycoplasmosis in poultry flocks.

flowchart TD
    A[Flock with respiratory signs or production loss], > B{Clinical suspicion of mycoplasmosis?}
    B, >|Yes| C[Collect samples: tracheal swabs, serum, air sac lesions]
    B, >|No| D[Routine surveillance]
    D, > E[Serological screening: RSA or ELISA]
    E, > F{Positive?}
    F, >|Yes| G[Confirm with HI or species-specific PCR]
    F, >|No| H[No further action]
    G, > I{Discordant results?}
    I, >|Yes| J[Perform culture and molecular typing]
    I, >|No| K[Diagnosis confirmed]
    C, > L[Direct detection: qPCR or LAMP]
    L, > M{Positive?}
    M, >|Yes| N[Quantify load and differentiate vaccine vs. wild-type if needed]
    M, >|No| O[Consider other pathogens: IBV, NDV, APEC]
    N, > P[Report and implement control measures]
    O, > Q[Perform multiplex respiratory panel]
    Q, > R[Identify co-infections]
    R, > P

Control and Prevention

Control of avian mycoplasmosis relies on biosecurity, flock management, vaccination, and antimicrobial therapy. Biosecurity measures include all-in-all-out production, strict quarantine of new stock, and prevention of contact with wild birds and fomites. Eradication programs based on serological testing and culling of positive flocks have been successful in some breeding operations but are costly.

Vaccination

Vaccination is widely used to reduce clinical signs and economic losses. Live attenuated vaccines (e.g., F-strain, ts-11, 6/85 for MG) are administered via eye drop, spray, or drinking water. These vaccines provide partial protection and can reduce egg production losses and airsacculitis. Recombinant vaccines have been developed to improve safety and efficacy. Evaluation of vaccination programs in layer pullets using a recombinant fowlpox-MG vaccine compared to commercially available F-strain live vaccines showed comparable protection with reduced risk of reversion to virulence [9]. For MS, a recombinant fowl adenovirus 4 expressing the P50 protein has been shown to protect chickens against MS infection, representing a promising vaccine candidate [10].

Antimicrobial Therapy

Antimicrobial treatment can reduce clinical signs but does not eliminate infection. Mycoplasmas are susceptible to macrolides, tetracyclines, pleuromutilins, and fluoroquinolones. However, antimicrobial resistance is an increasing concern. Pharmacokinetic/pharmacodynamic studies of a novel pleuromutilin derivative (APTM) against MG demonstrated favorable efficacy, highlighting the need for continued drug development [11]. The use of antimicrobials in poultry must comply with regulations to minimize selection for resistance and ensure food safety.

Alternative Approaches

Phytochemicals and natural compounds have been investigated for their anti-mycoplasmal properties. Scutellaria baicalensis extracellular vesicles were shown to attenuate MG-induced inflammation via inhibition of the TRPC1-STIM1/ORAI1 calcium channel pathway, suggesting a potential anti-inflammatory strategy [12]. Luteolin, a flavonoid, was found to target TatD nuclease and the MAPK pathway, exerting multifaceted anti-MG effects [13]. These approaches may complement conventional therapies in the future.

Conclusion

Avian mycoplasmosis remains a persistent challenge for the poultry industry worldwide. The complex pathogenesis involving co-infections, the ability of mycoplasmas to evade immunity, and the emergence of antimicrobial resistance necessitate integrated diagnostic and control strategies. Advances in molecular diagnostics, including multiplex real-time PCR and field-deployable LAMP assays, have improved detection accuracy and speed. Vaccination with live attenuated or recombinant vaccines, combined with stringent biosecurity, forms the cornerstone of control programs. Continued surveillance using molecular typing and serological monitoring is essential to track strain diversity and inform intervention strategies. The interplay between MG, MS, and other respiratory pathogens underscores the need for comprehensive diagnostic panels that can detect polymicrobial infections [1, 2, 14]. Future research should focus on developing next-generation vaccines, novel antimicrobials, and rapid point-of-care diagnostic tools to further mitigate the impact of avian mycoplasmosis on poultry production.

References

[1] Rodrigo CH, Kulappu Arachchige SN, Bushell RN, et al. Complex pathogen interactions in upper respiratory tract infections in commercial free-range layers: A cross-sectional study. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42190304/

[2] Zhang Y, Li Y, Wang Z, et al. Cryptosporidium baileyi and Mycoplasma synoviae co-infection enhances M. synoviae colonization and aggravates tissue damage in chickens. Front Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42158394/

[3] Edge AC, Moorman CE, Pacifici K, et al. Regional Pathogen Surveillance of Free-Ranging Wild Turkeys (Meleagris gallopavo) in North Carolina, USA. J Wildl Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41667058/

[4] Marín-Villa J, Alzate-Vargas JF, Ramírez TG, et al. Serological evidence and risk factors of Mycoplasma gallisepticum and Mycoplasma synoviae exposure in trafficked parrots and macaws in Colombia. Open Vet J. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41630737/

[5] Xin J, Zhang J, Liang S, et al. A multiplex TaqMan real-time PCR assay for differential identification of wild-type and vaccine strains of Mycoplasma gallisepticum. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41702344/

[6] Jing W, Cai Q, Liang Y, et al. High-throughput colorimetric LAMP detection of Mycoplasma gallisepticum with intelligent algorithm-assisted analysis. Anal Methods. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41891257/

[7] Mayne R, Pant SD, Huang J, et al. A field-ready colourimetric LAMP assay for detection of Mycoplasma gallisepticum using rapid DNA extraction. Res Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41785617/

[8] Stefani E, Morales-Arce AY, Nai G, et al. Molecular typing of Mycoplasma synoviae in industrial and backyard poultry: a 14-year study in Italy. Appl Environ Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41817199/

[9] Hashish A, Chaves M, Osemeke O, et al. Evaluation of Vaccination Programs in Layer Pullets Using Recombinant Fowl-Pox Mycoplasma gallisepticum Vaccine in Comparison to Commercially Available F-Strain Live Vaccines. Avian Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41973009/

[10] Liu Y, Li W, Li G, et al. Protection of chickens against M. synoviae infection by vaccination with a recombinant fowl adenovirus 4-P50. Microb Pathog. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41887300/

[11] Yang W, Ding H, Ma X, et al. Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative APTM against Mycoplasma gallisepticum. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41650639/

[12] Xu F, Bao L, Yao Y, et al. Mechanism of Scutellaria baicalensis extracellular vesicles in attenuating Mycoplasma gallisepticum-induced inflammation via TRPC1 - STIM1/ORAI1 channel inhibition. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41905072/

[13] Liu W, Wang S, Hu J, et al. Targeting TatD nuclease and the MAPK Pathway: Luteolin multifaceted approach against Mycoplasma gallisepticum infection. Poult Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41548475/

[14] Hartady T, Sugandi SD, Viqih M. A Case of Avian Influenza Co-Infection and Multifactorial Diseases in a Broiler Chicken Farm in Majalengka, West Java, Indonesia. Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42076736/

[15] Adelman JS, Henschen AE, Tillman FE Jr, et al. The devil you know: a longer history of pathogen coevolution predicts higher behavioural tolerance of infection among host populations. Biol Lett. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42124517/